Last reviewed · How we verify
NCT07278505: SCANS
Study of Cannabidiol and Neuroimaging on Stress
Phase 1, PHASE2 trial testing Cannabidiol in Early Life Adversity in 160 participants. Currently enrolling.
28 February 2030
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 160 |
| Start date | 28 October 2025 |
| Primary completion | 28 February 2030 |
| Estimated completion | 28 February 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cannabidiol (CANNABIDIOL) — full drug profile →
- Placebo
Conditions studied
- Early Life Adversity — all drugs for Early Life Adversity →
- Trauma — all drugs for Trauma →
- Stress — all drugs for Stress →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
Adults 18 to 25, any sex, with Early Life Adversity or Trauma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dysregulation in stress responsivity is a growing psychiatry-transdiagnostic fundamental phenomenon, with limited therapeutic strategies. With the legalization of medical and recreational cannabis, many people consume cannabidiol (CBD; a nonintoxicating cannabinoid) to alleviate stress response, without the benefit of scientific guidance. To address this gap, the investigators propose a rigorous translational neuroscience study in a clinical high-risk population to define the roles of CBD in stress response with mechanisms of mesocorticolimbic-network function and hierarchy, neurometabolic, endocrine, and behavior, building upon convergent evidence from animal models and human evidence from our laboratories.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07278505
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cannabidiol
Trials testing the same drug.
- NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
- NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting
- NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting
- NCT06854783 — Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers · Phase 1 · completed
- NCT06108349 — Topical Cannabidiol for Treating Carpal Tunnel Syndrome · Phase 2 · not yet recruiting
Other recruiting trials for Early Life Adversity
Currently open trials in the same condition.
- NCT05259436 — Collaborative Approach to Examining Adversity and Building Resilience Study · NA · active not recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07278505 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07278505.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing